Create a concise presentation ideally only 5 slides. The presentation is for a pharmaceutical advisory board. Mt section involves reviewing the latest chronic hepatitis B guidelines in particular EASL, AASLD, APASL, WHO and Australian. The company is looking at insights regarding Bepirovirsen from a guideline perspective is needs to focus around quantitative HBsAg, monitoring post NA cessation and HCC surveillance. My slides need to frame the discussion for answering the following: Based on Ph3 clinical data how will this inform potential guidelines and treatment algorithms. To discuss emerging therapies and future directions in CHB management, and how these can be integrated into updated guidelines.Β I have attached my slides from the previous years adboard they will need updating and adjusting.
Create a concise presentation ideally only 5 slides. The presentation is for a pharmaceutical advisory board. Mt section involves reviewing the latest chronic hepatitis B guidelines in particular EASL, AASLD, APASL, WHO and Australian. The company is looking at insights regarding Bepirovirsen from a guideline perspective is needs to focus around quantitative HBsAg, monitoring post NA cessation and HCC surveillance. My slides need to frame the discussion for answering the following: Based on Ph3 clinical data how will this inform potential guidelines and treatment algorithms. To discuss emerging therapies and future directions in CHB management, and how these can be integrated into updated guidelines.Β I have attached my slides from the previous years adboard they will need updating and adjusting.
Created using ChatSlide
The presentation will offer an in-depth exploration of the latest Chronic Hepatitis B (CHB) treatment guidelines, encapsulating updates from EASL, AASLD, and APASL 2026. It will delve into the significance of quantitative HBsAg in therapy decisions, emerging therapies like Bepirovirsen, and potential adjustments to existing protocols. Further, a focus will be placed on HCC surveillance techniques, evaluating risk factors, and optimization strategies. The session will conclude with a...